论文部分内容阅读
目的探讨了卡培他滨联合奥沙利铂治疗进展期胃癌疗效分析以及安全性。方法 102例进展期胃癌患者随机分为两组,对照组和治疗组,每组患者51例,治疗组采用卡培他滨联合奥沙利铂进行治疗,对照组采用奥沙利铂进行治疗,所有患者治疗3个月后进行疗效以及安全性评估。结果治疗组和对照的治疗有效率分别为72.54%和56.96%,与对照组相比较,治疗组有效率明显增加,具有统计学意义(P<0.05)。两组患者均出现了骨髓抑制、消化道系统以及手足综合征等不良反应,两组比较无统计学差异(P>0.05)。结论卡培他滨联合奥沙利铂治疗进展期胃癌疗效显著,且毒副作用可以耐受,值得临床推广使用。
Objective To investigate the efficacy and safety of capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer. Methods 102 patients with advanced gastric cancer were randomly divided into two groups, control group and treatment group, 51 patients in each group. The treatment group was treated with capecitabine combined with oxaliplatin, the control group was treated with oxaliplatin, All patients were treated for 3 months after the efficacy and safety assessment. Results The effective rates of the treatment group and the control group were 72.54% and 56.96%, respectively. Compared with the control group, the effective rate of the treatment group was significantly increased (P <0.05). There were no adverse reactions such as myelosuppression, digestive tract system and hand-foot syndrome in both groups. There was no significant difference between the two groups (P> 0.05). Conclusion Capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer has significant curative effect and tolerable side effects. It is worth to be used clinically.